Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy
Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Taylor & Francis Group
2024-12-01
|
| سلاسل: | Journal of Dermatological Treatment |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2424338 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|